NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients

Antiviral Inhibitory Capacity of CD8+ T cells Predicts the Rate of CD4+ T-Cell Decline in HIV-1 Infection

(2012) Hongbing Yang et al.   JOURNAL OF INFECTIOUS DISEASES

Initial HIV-1 Antigen-Specific CD8+ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication

(2012) S. A. Freel et al.   JOURNAL OF VIROLOGY

Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir

(2011) Deborah Persaud et al.   AIDS

A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune

(2011) Jonathan B Angel et al.   AIDS

SPICE: Exploration and analysis of post-cytometric complex multivariate datasets

(2011) Mario Roederer et al.   CYTOMETRY PART A

Factors Associated With Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial

(2011) Jonathan Z. Li et al.   JOURNAL OF INFECTIOUS DISEASES

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

(2010) Tae-Wook Chun et al.   AIDS

Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine

(2010) Laura Papagno et al.   AIDS

Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates

(2010) Aggeliki Spentzou et al.   JOURNAL OF INFECTIOUS DISEASES

Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination

(2010) S. A. Freel et al.   JOURNAL OF VIROLOGY

Proliferation Capacity and Cytotoxic Activity Are Mediated by Functionally and Phenotypically Distinct Virus-Specific CD8 T Cells Defined by Interleukin-7R  (CD127) and Perforin Expression

(2010) C. Cellerai et al.   JOURNAL OF VIROLOGY

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

(2009) Brigitte Autran et al.   AIDS

Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys

(2009) H-B Wang et al.   GENE THERAPY

Distinct Profiles of Cytotoxic Granules in Memory CD8 T Cells Correlate with Function, Differentiation Stage, and Antigen Exposure

(2009) A. Harari et al.   JOURNAL OF VIROLOGY

Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients

(2009) Bénédicte Puissant-Lubrano et al.   VACCINE

Improved Measures of Quality of Life, Lipid Profile, and Lipoatrophy After Treatment Interruption in HIV-Infected Patients With Immune Preservation: Results of ACTG 5170

(2008) Daniel J Skiest et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

(2008) Alexandre Harari et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

(2008)   LANCET

Phenotype and function of protective T cell immune responses in HIV

(2008) Michael R Betts et al.   Current Opinion in HIV and AIDS